Central nervous system and autonomic nervous system effects of amantadine and of some standard anti-Parkinson drugs.
D000547:Amantadine / Q000494:pharmacology*; D000818:Animals; D000978:Antiparkinson Agents / Q000494:pharmacology*; D001285:Atropine / Q000494:pharmacology; D001341:Autonomic Nervous System / Q000187:drug effects*; D001831:Body Temperature / Q000187:drug effects; D002217:Carbachol / Q000037:antagonists & inhibitors; D002490:Central Nervous System / Q000187:drug effects*; D004295:Dihydroxyphenylalanine / Q000494:pharmacology; D004347:Drug Interactions; D005769:Gastrointestinal Motility / Q000187:drug effects; D008297:Male; D008464:Mecamylamine / Q000494:pharmacology; D051379:Mice; D009184:Mydriatics / Q000494:pharmacology; D009538:Nicotine / Q000037:antagonists & inhibitors; D010095:Oxotremorine / Q000037:antagonists & inhibitors; D010640:Phenothiazines / Q000494:pharmacology; D011680:Pupil / Q000187:drug effects; D051381:Rats; D014282:Trihexyphenidyl / Q000494:pharmacology
D000978:Antiparkinson Agents; D009184:Mydriatics; D010640:Phenothiazines; D010095:Oxotremorine; D004295:Dihydroxyphenylalanine; D008464:Mecamylamine; D009538:Nicotine; D014282:Trihexyphenidyl; D001285:Atropine; D002217:Carbachol; D000547:Amantadine